Methoden zur Bestimmung des Faktors XIII/XIIIa

M. Wilmer; V. Schröder; H. P. Kohler

doi:10.1055/s-0037-1622004

Hämostaseologie, Table of Contents

Hamostaseologie 2002; 22(01): 18-28
DOI: 10.1055/s-0037-1622004

Original Article

Schattauer GmbH

Methoden zur Bestimmung des Faktors XIII/XIIIa

Methods for the determination of factor XIII/XIIIa

M. Wilmer

¹Pentapharm Ltd., Abteilung F&E Hömostase und Test-Kit-Entwicklung (Laborleitung: Dr. rer. nat. Marianne Wilmer), Basel

,

V. Schröder

²Thromboselabor, Departement Klinische Forschung (Laborleitung: Prof. Dr. phil. nat. André Haeberli) Universität Bern, Inselspital, Schweiz

,

H. P. Kohler

²Thromboselabor, Departement Klinische Forschung (Laborleitung: Prof. Dr. phil. nat. André Haeberli) Universität Bern, Inselspital, Schweiz

› Author Affiliations

Abstract

Zusammenfassung

Aktivierter Blutgerinnungsfaktor XIII (FXIIIa), eine Transglutaminase, quervernetzt in der letzten Phase der Sekundärhämostase die Fibrinpolymere durch Bildung intermolekularer Amidbindungen zwischen Glutaminund Lysinresten zu einem komplex strukturierten, dreidimensionalen Gerinnsel. Die dadurch gesteigerte Gerinnselfestigkeit wird durch den kovalenten Einbau von Zytoskelettbestandteilen wie Aktin und Myosin weiter erhöht. Darüber hinaus schützt der FXIIIa-abhängige Einbau antifibrinolytisch wirkender Faktoren wie α₂-Antiplasmin und Thrombin-aktivierbarer Fibrinolyseinhibitor (TAFI) vor vorzeitiger Lyse des Gerinnsels. Die kovalente Vernetzung der Fibrinpolymere mit Adhäsionsproteinen der extrazellulären Matrix (z. B. Fibronektin, Kollagen, Vitronektin, von-Willebrand-Faktor) fixiert das Gerinnsel am Ort der Gefäßläsion und unterstützt den Regenerationsprozess des Gewebes. Diese vielfältigen Funktionen von FXIIIa zeigen seine zentrale Bedeutung in der Hämostase. Im vorliegenden Übersichtsartikel werden Tests zur Erfassung der funktionellen Aktivität, Konzentration und zur Identifizierung des FXIII-Val34Leu-Polymorphismus vorgestellt.

Summary

Activated factor XIII (FXIIIa) plays an important role in the final stage of the coagulation cascade by covalent crosslinking of fibrin strands. As a transglutaminase FXIIIa catalyses the generation of intermolecular amide bonds between lysine and glutamine residues resulting in a complex three-dimensional clot structure. Enhanced clot stability is supported by covalent binding of cytosceleton factors like actin and myosin. Moreover, the clot is protected against premature lysis by the incorporation of fibrinolysis inhibitors like α₂-antiplasmin and thrombin activatable fibrinolysis inhibitor (TAFI). A covalent crosslinking of the fibrin strands with extracellular matrix proteins like fibronectin, vitronectin, collagen and von Willebrand factor (vWF) immobilizes the clot at the site of injury. Moreover FXIII supports the healing process of damaged tissue. In this review assays for determination of FXIIIa activity, FXIII concentration and identification of the FXIIIVal34Leu polymorphism are shown.

Schlüsselwörter

Faktor XIII - Transglutaminase - FXIII-Mangel - FXIII-Val34Leu-Polymorphismus

Keywords

Factor XIII - transglutaminase - FXIII deficiency - FXIII-Val34Leu polymorphism

Full Text

References

Literatur
1 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-72.
2 Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: Specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905.
3 Anwar R, Miloszewski KJA. FXIII Deficiency. Br J Haematol 1999; 107: 468-84.
4 Ariëns RAS, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-6.
5 Ballerini G, Guerra S, Meduri P, Rippa M. Application of a method for transamidase assay to the determination of the plasma factor XIII activity in normal and pathologic conditions. Lab 1983; 10: 501-504.
6 Ballerini G, Gemmati D, Moratelli S, Morelli P, Serino ML. A photometric method for the dosage of factor XIII applied to the study of chronic hepatopathies. Thromb Res 1995; 78: 451-6.
7 Balogh I, Szôke G, Kárpáti L, Wartiovaara U, Katona E, Komáromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96: 2479-86.
8 Barbui T, Cartei G, Chisesi T, Dini E. Electroimmunoassay of plasma subunits-A and -S in a case of congenital fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1974; 32: 124-31.
9 Barthels M, Östereich C, Steinke M, Poliwoda H. Clinical evaluation of a new photometric assay for plasma factor XIII. In FXIII. McDonagh J, Seitz R, Egbring R. (Hrsg) Stuttgart, New York: Schattauer; 1993: 129-33.
10 Beck E, Duckert F, Vogel A, Ernst M. Der Einfluss des fibrinstabilisierenden Faktors (FSF) auf Funktion und Morphologie von Fibroblasten in vitro. Z Zellforsch 1962; 57: 327-46.
11 Bockenstedt P, McDonagh J, Handin RI Binding. and covalent cross-linking of purified von Willebrand factor to native monomeric collagen. J Clin Invest 1986; 78: 551-6.
12 Calatzis A, Gödje O, Haas S, Fuchs A, Reichart B. Erhöhung der Gerinnselfestigkeit vor und nach herzchirurgischen Eingriffen durch Zusatz von Faktor XIII in vitro. In Egbring R, Seitz R, Wozniak G. (Hrsg) Klinische Aspekte des Faktor-XIII-Mangels. Freiburg: Karger; 1999: 55-62.
13 Carlebjörk G. A precise routine method for determination of F XIII activity in plasma. Thromb Res 1981; 21: 507-11.
14 Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. FXIII Val34Leu: a novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-6.
15 Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
16 Choi J, Choi GH, Woo KM, Park SC. Development of a solid-phase colorimetric assay for the screening of transglutaminase activities. Seoul J Med 1992; 33: 167-73.
17 Cohen I, Blankenberg TA, Borden D, Kahn DR, Veis A. Factor XIIIa-catalyzed crosslinking of platelet and muscle actin. Regulation by nucleotides. Biochim Biophys Acta 1980; 628: 365-75.
18 Cooke RD, Holbrook JJ. Calcium and the assay of human plasma clotting factor XIII. Biochem J 1974; 141: 71-8.
19 Corral J, Gonzales-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-7.
20 Dempfle CE, Harenberg J, Hochreuter K, Heene DL. Microtiter assay for measurement of factor XIII activity in plasma. J Lab Clin Med 1992; 119: 522-8.
21 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1969; 5: 179-86.
22 Duckert F. Assays for fibrin stabilizing factor (factor XIII). In Bang NU. (Hrsg) Thrombosis and Bleeding Disorders: Theory and Methods. Stuttgart, New York: Thieme; 1971: 262-7.
23 Dvilansky A, Britten AFH, Loewy AG. FXIII assay by an isotope method. Heparin inhibition of factor XIII activation. Thromb Diath Haemorrh 1972; 28: 256-64.
24 Egbring R, Schmidt W, Havemann K. Die vereinfachte radiologische Faktor-XIII-Bestimmung und ihre klinische Anwendung bei kongenitalem Faktor-XIII-Mangel. Blut 1973; XXVII: 6-19.
25 Ehrenforth S, Krause M, Herrmann FH, Wulff K, Zwinge B, Scharrer I. Pathogenesis of primary pulmonary embolism: impact of the factor XIII: Val34Leu polymorphism. Haemostasis 2000; 30: 30.
26 Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
27 Fésüs L, Folk JE. Synthetic glutamine peptides as substrates for the kinetic determination of blood coagulation factor XIII. Clin Chem 1985; 31: 2044-5.
28 Fickenscher K, Aab A, Stüber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991; 65: 535-40.
29 Francis JL. The detection and measurement of factor XIII activity: a review. Med Lab Sci 1980; 37: 137-47.
30 Franco RF, Reitsma PH, Laurenço D, Maffei FH, Morelli V, Tavella MH, Araújo AG, Piccinato CE, Zago MA. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 1999; 81: 676-9.
31 Gutzman M, Pollema C, Ruzicka J, Christian GD. Sequential injection technique for auto mation of complex analytical procedures: fluorometric assay for factor thirteen. Talanta 1993; 40: 81-7.
32 Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of von Willebrand factor to fibrin. Blood 1986; 68: 95-101.
33 Hartert H. Blutgerinnungsstudien mit der Thromboelastographie, einem neuen Untersuchungsverfahren. Klin Wochenschr 1948; 26: 577-83.
34 Hartert H. Rheo-simulation: a new method for the assay of clotting process and factor XIII. Biorheology 1974; 11: 355-60.
35 Heins M, Fahron U, Withold W, Rick W. Optimization of a new continuous UV assay for the determination of blood coagulation factor XIII activity in human plasma. Eur J Clin Chem Clin Biochem 1994; 32: 479-83.
36 Hellstern P, Schilz K, von Blohn G, Wenzel E. Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode. Thromb Haemost 1983; 50: 563-6.
37 Henry M, Morange PE, Canavy I, Alessi MC, Juhan-Vague I. Rapid detection of factor XIII Val34Leu by allele specific PCR. Thromb Haemost 1999; 81: 463.
38 Ichinose A, Aoki N. Reversible cross-linking of _α2-plasmin inhibitor to fibrinogen by fibrin- stabilizing factor. Biochim Biophys Acta 1982; 706: 158-64.
39 Ihalainen J, Siitari H, Laine S, Syvänen AC, Palotie A. Towards automatic detection of point mutations: use of scintillating microplates in solid-phase minisequencing. Biotechniques 1994; 16: 938-43.
40 Ikematsu S, McDonagh RP, Reisner HM, Skrzynia C, McDonagh J. Immunochemical studies of human factor XIII: Radioimmunoassay for the carrier subunit of the zymogen. J Lab Clin Med 1981; 97: 662-71.
41 Janssen CL, Masure R. Enzymatic method for the quantitative determination of factor XIII. Application to a familial deficiency. Path Europ 1970; 5: 315-30.
42 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-70.
43 Karges HE. Blood coagulation F XIII: determination by clot stability assays. In Bergmeyer HE. (Hrsg) Methods of Enzymatic Analysis, Vol V. Weinheim: Verlag Chemie; 1984: 400-10.
44 Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000; 46: 1946-55.
45 Katona E, Haramura G, Kárpáti L, Fachet J, Muszbek L. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost 2000; 83: 268-73.
46 Keski-Oja J, Mosher DF, Vaheri A. Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell 1976; 9: 29-35.
47 Kohler HP, Ariëns RAS, Whitaker P, Grant PJ. A common coding polymorphism in the factor XIII A-subunit gene (FXIII Val34Leu) affects cross-linking activity. Thromb Haemost 1998; 80: 704.
48 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
49 Lasch HG, Huth K, Heene DL, Müller-Berghaus G, Hörder MH, Janzarik H, Mittermayer C, Sandritter W. Die Klinik der Verbrauchskoagulopathie. DMW 1971; 96: 715-27.
50 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
51 Lee KN, Birckbichler PJ, Patterson K. Colorimetric assay of blood coagulation factor XIII in plasma. Clin Chem 1988; 34: 906-10.
52 Lorand L, Campbell LK. Transamidating enzymes. Rapid chromatographic assays. Anal Chem 1971; 44: 207-20.
53 Lorand L, Campbell-Wilkes LK, Cooperstein L. A filter assay for transamidating enzymes using radioactive amine substrates. Anal Biochem 1972; 50: 623-31.
54 Lorand L, Lockridge OM, Campbell LK, Myhraman R, Bruner-Lorand J. Transamidating enzymes. A continuous fluorescent method suited for automating measurements of factor XIII in plasma. Anal Biochem 1971; 44: 221-31.
55 Lorand L, Parameswaran KN, Velasco PT, Hsu LKH, Siefring GE. New colored and fluorescent amine substrates for activated fibrin stabilizing factor (factor XIIIa) and for transglutaminase. Anal Biochem 1983; 131: 419-25.
56 Lorand L, Urayama T, De Kiewiet JWC, Nossel HL. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest 1969; 48: 1054-64.
57 Lorenz S. Faktor XIII bei Colitis ulcerosa – Pilotstudie zur Substitution mit FXIII-Konzentrat. In Egbring R, Seitz R, Wozniak G. (Hrsg) Klinische Aspekte des Faktor-XIII-Mangels. Freiburg: Karger; 1999: 194-202.
58 McCormack LJ, Kain K, Catto AJ, Kohler HP, Stickland MH, Grant PJ. Prevalence of FXIII V34L in populations with different cardiovascular risk. Thromb Haemost 1998; 80: 523-4.
59 McDonagh J, McDonagh RP, Delâge JM, Wagner RH. Factor XIII in human plasma and platelets. J Clin Invest 1969; 48: 940-6.
60 Mikkola H, Syrjälä M, Rasi V, Vahtera E, Hämäläinen E, Peltonen L, Palotie A. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84: 517-25.
61 Miraglia C, Greenberg CS. Measurement of blood coagulation factor XIIIa formation in plasma containing glycyl-L-prolyl-L-arginyl-Lproline. Anal Biochem 1985; 144: 165-71.
62 Mosher DF, Schad PE. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa. J Clin Invest 1979; 64: 781-7.
63 Mosher DF. Action of fibrin-stabilizing factor on cold-insoluble globulin and alpha 2-macroglobulin in clotting plasma. J Biol Chem 1976; 251: 1639-45.
64 Mousli S, Wakid NW. Ammonia production during clot retraction and its use in assay of fibrinoligase. Clin Chem 1977; 23: 1739-43.
65 Mui PTK, Ganguly P. Cross-linking of actin and fibrin by fibrin-stabilizing factor. Am J Physiol 1977; 233: H346-H9.
66 Müller-Berghaus G, Pötzsch B. (Hrsg) Hämostaseologie: Molekulare und zelluläre Mechanismen, Pathophysiologie und Klinik. Berlin, Heidelberg: Springer; 1999
67 Murdock PJ, Owens DL, Chitolie A, Hutton RA, Lee CA. Development and evaluation of ELISAs for factor XIIIA and XIIIB subunits in plasma. Thromb Res 1992; 67: 73-9.
68 Muszbek L, Adány R, Mikkola H. Novel aspects of blood coagulation factor XIII. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33: 357-421.
69 Muszbek L, Polgár J, Fésüs L. Kinetic determination of blood coagulation factor XIII in plasma. Clin Chem 1985; 31: 35-40.
70 Muszbek L, Yee VC, Hevessy Z. Blood Coagulation Factor XIII: Structure and Function. Thromb Res 1999; 94: 271-305.
71 Nishida Y, Ikematsu S, Fukutake K, Fujimaki M, Fukutake K, Kakishita E. A new rapid and simple assay for factor XIII activity using dansylcadaverine incorporation and gel filtration. Thromb Res 1984; 36: 123-31.
72 Ostermann H. Faktor-XIII-Plasmawerte bei Patienten mit Colitis ulcerosa Diagnostische Ergebnisse der Colitis-ulcerosa-Studien. In Egbring R, Seitz R, Wozniak G. (Hrsg) Klinische Aspekte des Faktor-XIII-Mangels. Freiburg: Karger; 1999: 207-12.
73 Päge S, Schwenke E. Substitution mit FXIII-Konzentrat eine adjuvante Behandlung bei therapieresistenter aktiver Colitis ulcerosa. In Egbring R, Seitz R, Wozniak G. (Hrsg) Klinische Aspekte des Faktor-XIII-Mangels. Freiburg: Karger; 1999: 202-6.
74 Retzinger GS, Cook BC, Smith RE, McGinnis MC. Quantitation of plasma factor XIIIa activity using fibrin-coated microscopic latex beads. Anal Biochem 1991; 195: 18-23.
75 Robbins KC. A study of the conversion of fibrinogen to fibrin. Am J Physiol 1944; 142: 581-8.
76 Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin stabilizing factor. J Clin Invest 1980; 65: 290-7.
77 Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
78 Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104: 467-74.
79 Sheltawy MJ, Miloszewski K, Losowsky MS. Factors affecting factor XIII assay by dansyl cadaverine incorporation. Thromb Diath Haemorrh 1972; 28: 483-8.
80 Sipka S, Padar E, Szilagyi T. The effect of colloidal gold on blood coagulation. Haematologia 1976; 10: 361-3.
81 Skrzynia C, Reisner HM, McDonagh J. Characterization of the catalytic subunit of factor XIII by radioimmunoassay. Blood 1982; 60: 1089-95.
82 Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS. A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem 1992; 205: 466-71.
83 Solleder E, Demuth D, Pfeiffer C, Bomhard M, Mayer J, Eller T, Brauer P, Keller F, Grün J, Fickenscher K, Wagner C. Klinische Prüfung eines neuen photometrischen Tests zur Bestimmung der Faktor XIII-Aktivität im Plasma. Lab med 1992; 16: 48-53.
84 Song YC, Sheng DQ, Taubenfeld SM, Matsueda GR. A microtiter assay for factor XIII using fibrinogen and biotincadaverine as substrates. Anal Biochem 1994; 223: 88-92.
85 Syvänen AC, Aalto-Setala K, Harju L, Kontula K, Soderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990; 8: 684-92.
86 Takagi J, Saito Y, Takashi K, Inada Y. Modification of transglutaminase assay: use of ammonium sulfate to stop the reaction. Anal Biochem 1986; 153: 295-8.
87 Takahashi H, Sakuragawa N, Shibata A. Assay of plasma factor XIII activity with dansyl cadaverine incorporation. Nippon Ketsueki Gakkai Zasshi 1979; 42: 516-24.
88 Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
89 Thies HA, Richter U. Erworbener Faktor-XIII-Mangel und klinische Chirugie. Med Welt 1981; 32: 250-5.
90 Tyler HM. Fibrin crosslinking demonstrated by thrombelastography. Thromb Diath Haemorrh 1969; 22: 398-400.
91 Valnickova Z, Enghild JJ. Human procarboxipeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed crosslinking to fibrin. J Biol Chem 1998; 273: 27220-4.
92 van Wersch JW. Analytical and clinical utility of a photometric assay for blood coagulation factor XIII. Eur J Clin Chem Clin Biochem 1993; 31: 467-71.
93 Velasco PT, Karush F, Lorand L. Transamidating activities of factor XIIIa and of transglutaminases, measured by an ELISA procedure. Biochem Biophys Res Commun 1988; 152: 505-11.
94 Wagner B, Seyfert U, Gosse M, Wenzel E, Fickenscher K, Ruhl HG. Determination of factor XIII activity by a new photometric assay in plasma and platelets of healthy blood donors. Thromb Res 1994; 74: 169-74.
95 Walls WD, Losowsky MS. Abnormalities of fibrin stabilization in liver and kidney disease: a comparison of two different methods. Clin Sci 1969; 37: 837-46.
96 Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Val34Leu with decreased risk of myocardial infarction in finnish males. Arteriosclerosis 1999; 142: 295-300.
97 Wilmer M, Rudin K, Kolde HJ, Poetzsch B, Lenz W, Moessmer G, Meili E, Egbring R, Gempeler-Messina P, Gempeler M, Bastian S, Kohler HP. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res 2001; 102: 81-91.
98 Yamada K, Meguro T. A new assay method for factor XIII using a fluorescence polarization analyzer, based on change in the rotary brownian motion. Thromb Res 1977; 11: 557-66.
99 Yorifuji H, Anderson K, Lynch GW, Van De Water L, McDonagh J. B Protein of factor XIII: Differentiation between free B and complexed B. Blood 1988; 72: 1645-50.